We were delighted to speak with Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss the recent post-hoc analysis of cenobamate for uncontrolled focal seizures, and its intended place in the treatment landscape for epilepsy.
The abstract entitled: ‘Efficacy of Cenobamate for Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What did the findings of the recent global, open-label phase 3 study teach us about the efficacy and safety of cenobamate? (0:15)
- What is the rationale for the dose escalating strategy with cenobamate? (5:45)
- What was the rationale for the post-hoc analysis? (6:47)
- What were the findings of this analysis? (7:41)
- What questions remain unanswered? (8:45)
Disclosures: Michael Sperling has received compensation for speaking at CME programs from Neurology Live, Medscape, Projects for Knowledge, International Medical Press, Eisai, and UCB Pharma; and is an advisor for scientific publications for Neurelis; consults for Medtronic with payments to Thomas Jefferson University; and has received research support from Eisai; Medtronic; Neurelis; SK Life Science; Takeda; Xenon; Cerevel; UCB Pharma; and Engage Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
